Equities

CG Oncology Inc

CGON:NSQ

CG Oncology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.47
  • Today's Change1.13 / 3.49%
  • Shares traded404.18k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform7
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for CG Oncology Inc have a median target of 65.50, with a high estimate of 86.00 and a low estimate of 51.00. The median estimate represents a 95.70% increase from the last price of 33.47.
High156.9%86.00
Med95.7%65.50
Low52.4%51.00

Earnings history & estimates in USD

On Nov 12, 2024, CG Oncology Inc reported 3rd quarter 2024 losses of -0.300 per share.
The next earnings announcement is expected on Mar 31, 2025.
Average growth rate+35.61%
CG Oncology Inc reported annual 2023 losses of -15.65 per share on Mar 26, 2024.
More ▼

Revenue history & estimates in USD

CG Oncology Inc had 3rd quarter 2024 revenues of 43.00k. This missed the 104.00k consensus estimate of the 5 analysts following the company. This was 4,200.00% above the prior year's 3rd quarter results.
Average growth rate+17,553.24%
CG Oncology Inc had revenues for the full year 2023 of 204.00k. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.